Unknown

Dataset Information

0

Integrative proteomic and functional analyses provide novel insights into the action of the repurposed drug candidate nitroxoline in AsPC-1 cells.


ABSTRACT: We recently identified nitroxoline as a repurposed drug candidate in pancreatic cancer (PC) showing a dose-dependent antiproliferative activity in different PC cell lines. This antibiotic is effective in several in vitro and animal cancer models. To date, the mechanisms of nitroxoline anticancer action are largely unknown. Using shotgun proteomics we identified 363 proteins affected by nitroxoline treatment in AsPC-1 pancreatic cancer cells, including 81 consistently deregulated at both 24- and 48-hour treatment. These proteins previously unknown to be affected by nitroxoline were mostly downregulated and interconnected in a single highly-enriched network of protein-protein interactions. Integrative proteomic and functional analyses revealed nitroxoline-induced downregulation of Na/K-ATPase pump and ?-catenin, which associated with drastic impairment in cell growth, migration, invasion, increased ROS production and induction of DNA damage response. Remarkably, nitroxoline induced a previously unknown deregulation of molecules with a critical role in cell bioenergetics, which resulted in mitochondrial depolarization. Our study also suggests that deregulation of cytosolic iron homeostasis and of co-translational targeting to membrane contribute to nitroxoline anticancer action. This study broadens our understanding of the mechanisms of nitroxoline action, showing that the drug modulates multiple proteins crucial in cancer biology and previously unknown to be affected by nitroxoline.

SUBMITTER: Veschi S 

PROVIDER: S-EPMC7018951 | biostudies-literature | 2020 Feb

REPOSITORIES: biostudies-literature

altmetric image

Publications

Integrative proteomic and functional analyses provide novel insights into the action of the repurposed drug candidate nitroxoline in AsPC-1 cells.

Veschi Serena S   Ronci Maurizio M   Lanuti Paola P   De Lellis Laura L   Florio Rosalba R   Bologna Giuseppina G   Scotti Luca L   Carletti Erminia E   Brugnoli Federica F   Di Bella Maria Cristina MC   Bertagnolo Valeria V   Marchisio Marco M   Cama Alessandro A  

Scientific reports 20200213 1


We recently identified nitroxoline as a repurposed drug candidate in pancreatic cancer (PC) showing a dose-dependent antiproliferative activity in different PC cell lines. This antibiotic is effective in several in vitro and animal cancer models. To date, the mechanisms of nitroxoline anticancer action are largely unknown. Using shotgun proteomics we identified 363 proteins affected by nitroxoline treatment in AsPC-1 pancreatic cancer cells, including 81 consistently deregulated at both 24- and  ...[more]

Similar Datasets

| S-EPMC10706310 | biostudies-literature
| S-EPMC4032345 | biostudies-literature
| S-EPMC9874943 | biostudies-literature
| S-EPMC3164635 | biostudies-literature
| S-EPMC8472899 | biostudies-literature
| S-EPMC7072466 | biostudies-literature
2020-07-13 | GSE126082 | GEO
| S-EPMC9158531 | biostudies-literature
| S-EPMC10657403 | biostudies-literature
| S-EPMC9703714 | biostudies-literature